Table 2:
Infectivity of monovalent dengue vaccine candidates
Virus | Dose (log10 PFU) | No. subjects | % viremic | Mean peak virus titer log10 PFU/mL | % seroconverting |
---|---|---|---|---|---|
rDEN1Δ30 | 3 | 71 | 61 | 1.0 | 93 |
rDEN2/4Δ30 | 3 | 40 | 60 | 0.5 | 100 |
rDEN2Δ30 | 3 | 10 | 100 | 2.5 | 100 |
rDEN3/4Δ30 | 3 | 20 | 15 | 1.0 | 30 |
rDEN3/4Δ30 | 4 | 20 | 0 | n/a | 25 |
rDEN3Δ30/31 | 3 | 50 | 34 | 0.5 | 81 |
rDEN3–3’D4Δ30 | 3 | 20 | 20 | 0.6 | 80 |
rDEN4Δ30 | 3 | 50 | 26 | 0.7 | 93 |
rDEN4Δ30–200,201 | 5 | 20 | 0 | n/a | 100 |
rDEN4Δ30–4995 | 5 | 20 | 0 | n/a | 95 |